Targeted Next-Generation Sequencing Identifies Pathogenic Variants in Familial Congenital Heart Disease  by Blue, Gillian M. et al.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y VO L . 6 4 , N O . 2 3 , 2 0 1 4
ª 2 0 1 4 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 4 . 0 9 . 0 4 8Targeted Next-Generation Sequencing
Identiﬁes Pathogenic Variants in
Familial Congenital Heart Disease
Gillian M. Blue, MSC,*yz Edwin P. Kirk, MBBS, PHD,xk Eleni Giannoulatou, MENG, MPHIL, DPHIL,{#
Sally L. Dunwoodie, PHD,{**yy Joshua W.K. Ho, PHD,{# Desiree C.K. Hilton, PHD,*y Susan M. White, MBBS,zzxx
Gary F. Sholler, MBBS (HONS),*yz Richard P. Harvey, PHD,{**yy David S. Winlaw, MBBS, MD*yzABSTRACTFro
Ch
xD
Fa
Sy
Un
Wa
xxD
rel
Lis
Yo
MaBACKGROUND Many genes have been implicated in the development of congenital heart disease (CHD).
Next-generation sequencing offers opportunities for genetic testing but is often complicated by logistic and inter-
pretative hurdles.
OBJECTIVES This study sought to apply next-generation sequencing technology to CHD families with multiple
affected members using a purpose-designed gene panel to assess diagnostic potential for future clinical applications.
METHODS We designed a targeted next-generation sequencing gene panel for 57 genes previously implicated in CHD.
Probands were screened in 16 families with strong CHD histories and in 15 control subjects. Variants affecting protein-
coding regions were classiﬁed in silico using prediction programs and ﬁltered according to predicted mode of inheritance,
minor allele frequencies, and presence in databases such as dbSNP (Single Nucleotide Polymorphism Database) and ESP
(Exome Sequencing Project). Disease segregation studies were conducted in variants identiﬁed in CHD cases predicted to
be deleterious and with minor allele frequencies <0.1%.
RESULTS Thirteen potential disease-causing variants were identiﬁed in 9 families. Of these, 5 variants segregated with
disease phenotype, revealing a likely molecular diagnosis in 31% of this cohort. Signiﬁcant increases in the number of
“indels, nonsense, and splice” variants, as well as variants classiﬁed as “probably damaging” were identiﬁed in CHD cases
but not in control subjects. Also, there was a signiﬁcant increase in the total number of “rare” and “low” frequency
variants (minor allele frequencies <0.05) in the CHD cases.
CONCLUSIONS When multiple relatives are affected by CHD, a gene panel–based approach may identify its cause in
up to 31% of families. Identifying causal variants has implications for clinical care and future family planning. (J Am Coll
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AB BR E V I A T I O N S
AND ACRONYM S
CHD = congenital heart disease
CI = conﬁdence interval
DNA = deoxyribonucleic acid
ELN = elastin gene
MAF = minor allele frequency
NGS = next-generation
sequencing
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2499syndromic and nonsyndromic forms of CHD (3). The
majority of these genes encode transcription factors,
although genes in other categories have also been
implicated, such as those for structural proteins.
Next-generation sequencing (NGS) enables rapid
analysis of large amounts of genetic information. The
last few years have produced an explosion of research
using NGS technology, especially exome sequencing,
for novel gene discoveries in many genetic diseases.
Although one cannot dispute the advantage of exome
sequencing for gene discovery through its unbiased
approach, issues relating to coverage, analysis, and
storage of large amounts of data and reporting of
incidental ﬁndings complicate its use in the clinical
setting (4). In comparison, limiting the capture re-
gions to only those known to be associated with the
disease(s) of interest mitigates some of these issues,
making it a valuable and arguably more suitable
approach in the diagnostic arena (5). Coverage, both
in terms of depth as well as capture of on-target re-
gions, is far greater, and being able to supplement
missed NGS regions with Sanger sequencing further
ensures high conﬁdence in the results. Furthermore,
issues relating to reporting of incidental ﬁndings can
be avoided almost entirely as only disease-relevant
genes are screened. Numerous disease-targeted gene
panels are clinically available, including panels for
hereditary cancers (6), metabolic disorders (7), car-
diomyopathies (8), and aortopathies (9).SEE PAGE 2507NGS technology has been applied to the study of
both familial and sporadic forms of CHD (10,11). A
recent publication by Zaidi et al. (12) used exome
sequencing analysis in parent-offspring trios to
compare variants in 362 cases with severe sporadic
CHD to 264 control subjects. They identiﬁed a signiﬁ-
cant excess of protein-altering, deleterious de novo
mutations in known heart-expressing genes (odds
ratio: 7.5), implicating several hundred genes that
collectively may factor into w10% of sporadic CHD
cases. Although these ﬁndings, as well as similar
results relating to the contribution of rare and de
novo copy number variants (13,14), greatly advance
our understanding of sporadic forms of this di-
sease, they do not resolve the cause ofmost CHD cases.
Moreover, this information has little clinical relevance
as it is not directly applicable to families with CHD.
In this study, we set out to design the ﬁrst NGS
CHD gene panel comprising genes previously linked
to structural heart disease to assess this tool’s diag-
nostic potential in families with multiple affected
individuals and an apparently Mendelian pattern ofinheritance. Identifying the possible cause of
CHD in such families would have signiﬁcant
clinical relevance in terms of recurrence risk
estimates and family planning.
METHODS
STUDY PARTICIPANTS. Ethical approval for
this study was obtained from the Sydney
Children’s Hospitals Network Human Re-
search Ethics Committee (approval number
CHW/2006/123). Individuals with structural CHD and
family histories of CHD with an apparently Mendelian
inheritance pattern were selected from the Kids Heart
Research DNA (deoxyribonucleic acid) Bank. Families
were excluded if CHD cases were unable to be
conﬁrmed via echocardiography and/or if they
already had a deﬁnite or tentative genetic diagnosis.
Participating families included a proband with CHD,
an immediate family member affected by CHD, and a
minimum of 1 other family member (immediate or
extended) with CHD (mean number of affected family
members ¼ 4). In most cases, the proband was
selected for deoxyribonucleic acid (DNA) analysis but
in cases where DNA quantity was inadequate, an im-
mediate family member affected with the same or
similar phenotype was selected for analysis. A total of
16 CHD cases were included in this study, with the
number limited by the size of the targeted NGS cap-
ture kit used.
Contro l sub jects . To distinguish between possible
disease-causing variants and normal population
variations, 15 healthy control subjects from the Kids
Heart Research DNA Bank were screened using the
CHD panel. All control subjects had no self-reported
history of CHD within 3 generations. Principal com-
ponent analysis was performed to ensure the control
subjects and CHD cases were ethnically matched using
646 bi-allelic single nucleotide polymorphism posi-
tions that were present in HapMap (International
HapMap Project) samples. After projecting our data
onto 415 HapMap samples, no separation was evident
between cases and control subjects, suggesting
appropriate matching. Online Figure 1 shows the
results of the principal component analysis.
CHD PANEL DESIGN. Harnessing information from
various ﬁelds, 57 genes were included in the CHD
panel. (For a full list of genes included in the panel,
see Online Table 1.) We used the web application Sure
Design (Agilent Technologies, Santa Clara, California)
to create a custom SureSelect target enrichment
library of the 57 selected genes. Target parameters
were manipulated to optimize coverage of all coding
exons, 50 and 30 untranslated regions, as well as
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A repeat design at reduced stringency was performed
to cover missing target regions >80 base pairs.
SAMPLE PREPARATION. All genomic DNA samples
from the Kids Heart Research DNA Bank were
extracted from whole blood using the QIAamp DNA
Blood Midi kit (for 2-ml blood samples; Qiagen GmbH,
Hilden, Germany) and the DNA Isolation Kit for
Mammalian Blood (for 5- to 10-ml blood samples;
Roche Diagnostics, Indianapolis, Indiana) following
the manufacturer’s protocol. The quality and quan-
tity of the DNA samples were measured using the
NanoDrop 2000 spectrophotometer (Thermo Fisher
Scientiﬁc, Inc., Waltham, Massachusetts) and 3 mg of
DNA from each sample was used for analysis.
TARGETED NEXT-GENERATION SEQUENCING. Tar-
geted NGS (including library construction, cap-
ture, and sequencing) was carried out at Oxford
Gene Technologies (Oxfordshire, United Kingdom).
Enrichment of target regions and library preparation
was performed using the SureSelectXT2 Custom kit
(1kb-499kb,16) according to the SureSelect protocol
(version 1.2, Agilent Technologies). Library concen-
trations were determined using Agilent’s QPCR NGS
Library Quantiﬁcation Kit (G4880A) with each sample
at a ﬁnal concentration of 10 nmol/l. A HiSeq2000
sequencer was used to sequence the samples using
TruSeq chemistry and protocols (version 3, Illumina,
Inc., San Diego, California). The CHD cases and con-
trol subjects were analyzed separately with all CHD
cases grouped into 1 enrichment kit and sequencing
run and, subsequently, all control samples into
another enrichment kit and sequencing run.
DATA ANALYSIS AND FILTERING. Preliminary data
analysis (including read alignment, variant calling,
and annotation) was carried out by Oxford Gene
Technologies. (For detailed data analysis, see the
methods section of the Online Appendix).
All variants affecting protein-coding regions
for each sample were categorized into “novel” and
“known” variants according to their presence in dbSNP
(Single Nucleotide Polymorphism Database) 137. The
minor allele frequencies (MAF) of all known variants
were reported according to their presence in the
National Heart, Lung, and Blood Institute ESP (Exome
Sequencing Project) or according to dbSNP 137 if not
present in ESP. All variants were subjected to in silico
analysis, which included prediction programs such as
SIFT (J. Craig Venter Institute, La Jolla, California),
PolyPhen2 (Harvard Medical School, Boston, Massa-
chusetts), and Condel (Biomedical Genomics Group,
Barcelona, Spain), as well as Alamut (version 2.3,
revision 2, Interactive Biosoftware, Rouen, France) forsplicing predictions where appropriate. In addition,
literature reviews were conducted on each variant
to establish any previous association with CHD.
To compare the number and types of variants
between CHD cases and control subjects, non-
synonymous variants were further grouped according
to their PolyPhen2 scores and reported MAF in both
the 1,000 Genomes Project and ESP.
Despite the high coverage of target regions, copy
number variants analysis could not be conducted as
no baseline measure could be established due to the
higher coverage observed in all of the CHD cases
compared with the control subjects. Furthermore,
there were not enough samples to allow copy number
variants calling using CHD cases only.
STATISTICAL ANALYSIS. All data relating to the
number and types of variants observed in the CHD
cases versus control subjects were analyzed using
SPSS (version 21, IBM, Armonk, New York). Descrip-
tive statistics were obtained for each variant group.
Poisson log linear regression was applied to all
comparative analyses between groups in the CHD
cases versus control subjects. (Poisson regression is
used to model count data and as the number of
variants in each individual case and control are in
“count” format, this was the recommended model of
analysis.) The potential disease-causing variants
identiﬁed in the 5 families following the segregation
analyses were removed from the Poisson analysis,
thereby only comparing the variants of unknown sig-
niﬁcance between the CHD cases and control subjects.
VARIANT VALIDATION. Variants warranting further
investigation included novel variants predicted to be
“probably damaging” according to PolyPhen2 pre-
dictions or known variants predicted to be “probably
damaging” and with MAF <0.1%. All such variants
were conﬁrmed via bidirectional Sanger sequencing
and disease segregation studies were carried out on
all available family members. Variants considered to
be segregatingwith diseasewere present in all affected
family members and absent in unaffected mem-
bers. However, as CHD commonly features reduced
penetrance, variants present in unaffected family
members were considered, provided that the segre-
gation was consistent with inheritance in the family.
The primer sequences used to analyze each variant via
polymerase chain reaction are listed in Online Table 2.
RESULTS
CHD PANEL COVERAGE. In CHD cases, a minimum of
99.29% of target regions were covered to a depth of at
least 20with an average read depth of 1,873 in CHD
cases. Similarly, in control samples, a minimum of
TABLE 1 Mean Number of Variants Identiﬁed
Mean Number per
CHD Case
Mean Number per
Control Subject
Type of variant
Total coding variants 16.13  2.31 13.27  2.55
Novel 0.94  0.77 0.47  0.52
“Indels/nonsense/splice site” 0.75  0.17* 0.13  0.35
Classiﬁcation according to PolyPhen2
“Probably damaging” 3.13  1.02* 1.80  1.21
“Possibly damaging” 1.31  0.95 1.07  0.88
“Benign” 10.81  2.37 10.27  2.46
Classiﬁcation according to MAF
“Rare,” MAF <0.01 2.44  1.15 1.60  1.35
“Low frequency,” MAF ¼ 0.01–0.05 1.63  0.96† 0.60  0.91
“Common,” MAF >0.05 12.00  1.93 11.07  2.22
Values are mean  SD. *p < 0.05; †p < 0.01.
CHD ¼ congenital heart disease; MAF ¼ minor allele frequency.
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250198.22% of target regions were covered to a depth of at
least 20with an average read depth of 307. In terms
of individual gene coverage, 15 genes were covered
100%. Target regions for 20 genes were covered>99%,
target regions in 19 genes were covered >97%, and
target regions in 3 genes were covered >92%.
The majority of uncovered target regions in individual
genes were in the 50 and 30 untranslated regions as well
as upstream and downstream regions, with minimal
uncovered exonic regions.
NUMBER AND TYPES OF VARIANTS IDENTIFIED IN
CHD CASES AND CONTROLS. In total, 91 variants
affecting protein-coding regions were identiﬁed, 17 of
which were novel—with 10 variants unique to CHD
cases, 6 unique to control subjects, and 1 present in
several CHD cases as well as a single control. Many
known variants were present in multiple CHD cases
and control subjects, including 25 known variants
predicted to be “probably damaging” according to
various prediction programs. Online Table 3 lists all
the variants affecting protein-coding regions identi-
ﬁed in this study cohort along with the observed
frequencies in CHD cases versus control subjects, as
well as their reported frequencies according to their
ESP and PolyPhen2 scores and predictions. The vari-
ants affecting protein-coding regions identiﬁed in
each CHD case and control subject are presented in
Online Tables 4 and 5, respectively.
We calculated the mean number of variants for
each CHD case and control subject (Table 1). An indel
variant was identiﬁed in 2 control subjects (2 of 15 ¼
0.13 as per Table 1); however, no splicing or nonsense
variants were identiﬁed in any control subjects
compared with 2 nonsense variants in 2 CHD cases,
1 splicing variant in a single case, and 9 indels in
8 CHD cases (12 of 16 ¼ 0.75 as per Table 1). All vari-
ants were further classiﬁed according to their MAF
and nonsynonymous variants according to their
PolyPhen2 classiﬁcation.
COMPARISONS BETWEEN GROUPS OF VARIANTS IN
CHD CASES AND CONTROL SUBJECTS. Poisson log
linear regression revealed a signiﬁcant difference in
the “indels, nonsense, and splice” variants with
4.69 as many of these variants in the CHD cases
(95% conﬁdence interval [CI]: 1.03 to 21.36; p ¼ 0.05).
We also identiﬁed signiﬁcantly more “probably
damaging” variants with 1.63 as many in the CHD
cases than in control subjects (95% CI: 1.02 to 2.62;
p ¼ 0.04). There was a signiﬁcant difference in the
total number of “rare” and “low” frequency variants
(MAF <0.05) with 1.71 as many of these variants in
the CHD cases than in control subjects (95% CI: 1.12 to
2.61; p ¼ 0.01). Figure 1 shows the comparison in meannumber of variants per individual using the different
variant classiﬁcations for CHD cases and control
subjects.
LIKELY PATHOGENIC VARIANT ANALYSES. Thirteen
variants warranting further investigations were
identiﬁed in 9 of the 16 CHD cases. All 13 variants
were predicted to be “probably damaging” according
to the various prediction programs and with Poly-
Phen2 scores above 0.985. Of these, 6 variants were
novel and not present in dbSNP 137 or ESP. The
remaining 7 all had MAF <0.1% aside from 1 variant,
NKX2-5 R25C, which had a MAF ¼ 0.95%. As this
variant has previously been reported to be associated
with CHD (15–17), it was included for further analysis.
Disease segregation studies in the 13 variants
revealed 5 variants that cosegregated with disease
and are likely pathogenic variants. The diagnostic
performance of the CHD panel is therefore 31% (5 of
16 families). Table 2 lists the 13 variants for which
disease segregation studies were done, as well as
the respective MAF and segregation study results;
Figure 2 illustrates the pedigrees of the 5 families
segregating the likely pathogenic variants as well as
details on these variants. Pedigrees of the remaining
families in which segregation studies were conducted
but no likely pathogenic variants identiﬁed are illus-
trated in Online Figure 2.
DISCUSSION
The CHD gene panel is the ﬁrst tool of its kind to offer
families affected by Mendelian forms of CHD a
reasonable chance at a genetic diagnosis by efﬁciently
and effectively interrogating a large number of genes
linked to CHD through NGS technology use. We
consider gene panels more clinically applicable than
FIGURE 1 Comparisons of Variants of Unknown Signiﬁcance
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Poisson log linear regression was used to compare the groups of variants in the congenital heart disease (CHD) cases and control subjects (controls). Variants are
presented as means per individual across the various classiﬁcations. Interpretation of comparisons between groups should be taken in the context of the size of the
cohort (n ¼ 31): variants are classiﬁed according to PolyPhen2 predictions (A); variants are classiﬁed according to minor allele frequency (MAF) (B); and variants with
MAF <0.05 are classiﬁed according to PolyPhen2 (C). Error bars show 95% conﬁdence intervals. *p # 0.05; **p # 0.01.
TABLE 2
TBX5 D16
TBX5 Y40
MYH6 T13
NOTCH1 G
EVC2 R68
NOTCH1 G
ZFPM2 I22
TBX20 R4
SHOC2 I11
TFAP2b R2
MYOCD D1
NKX2-5 R
ELN (c.95
*Minor alle
conﬁrmed i
affected fam
ELN ¼ ela
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2502exome sequencing because of the quicker turnaround
times (due to reduced sequencing volume and asso-
ciated data analysis), higher and more reliable
coverage, and ability to avoid incidental ﬁndings. WeVariants Included in Disease Cosegregation Studies
MAF* Family Variant Segregation†
6G Novel 10006 Yes
7X Novel 10861 Yes
79M 0.0009 10861 No
1091S Novel 11387 No
7H 0.0008 11756 No
200R Novel 11756 Yes
7V 0.0008 11842 No
20X 0.00008 12944 No
2T 0.001 12944 No
85Q Known pathogenic
variant
12946 Yes
60N Novel 13041 No
25C 0.0095 13041 No
0-3C>G) Novel 12637 Yes
le frequencies according to ESP (Exome Sequencing Project). †Segregation was
f variants were present in all affected family members. If a variant was absent in an
ily member, the variant was not regarded as segregating with disease.
stin gene; MAF ¼ minor allele frequency.applied the CHD gene panel to families with strong
histories of structural heart disease in an attempt to
identify the variants responsible for their disease
(Central Illustration). The CHD panel was able to
identify variants that are likely the cause of CHD in
31% of the families analyzed. These results impor-
tantly provide a clear explanation for the CHD in the
family and conﬁrm the presumed mechanism of in-
heritance. The knowledge opens up options for future
pregnancies for those found to carry the familial
mutations (e.g., pre-implantation genetic diagnosis).
Furthermore, ﬁnding a causative mutation in certain
genes, such as in TBX5, NKX2-5, or TBX20, would
suggest screening for conduction abnormalities or
adult-onset cardiomyopathies in mutation-positive
family members, as conduction defects and cardio-
myopathies can occur in the absence of structural
CHD (18,19).
PATHOGENIC VARIANTS. The variant identiﬁed in
Family #12946, TFAP2b R285Q, is a known pathogenic
variant associated with Char syndrome, an autosomal
dominant disorder affecting the heart, hands, and
face. This variant is found in the basic domain,
a highly conserved region critical for DNA binding
(20). Affected individuals usually have 3 distinctive
FIGURE 2 Family Pedigrees and Variant Details for Families With Disease-Segregating Variants
ALCAPAPA / VSD / MAPCAS
01756
PTA / VSD
TOF
multiple
surgeries
Family 12946 – TFAP2β R285Q
heart related death
heart problems
PDA
surgically closed
ASD
Pacemaker
PDA
surgically closed;
toe syndactyly
PDA
closure via cath
+
+ +
+++
+ +
+
+
++++
+
+
+
+
+
normal
ECHO toe
syndactyly
+ + +
-
-
-
-
-- -
-
-
-
-
-
PDA
surgically
closed
02946
murmur detected
normal ECHO toe syndactyly
Family 12637 - ELN (c.950-3C>G) Family 11756 – NOTCH1 G200RFamily 10006 – TBX5 D166G
ASD/VSD
Pacemaker
00861
ASD repair
Pacemaker
died age 27 yrs
? heart related
? ‘holes in heart’
no contact
died
during
CHD
surgery
perimembranous
VSD (small)
ASD (surgery)
perimembranous
VSD (spont
closure)
ASD
muscular
VSD (spont
closure)
02637
SVAS
surgery
No abnormality on
cardiac review
SVAS
surgery age 12  yrs
SVAS
surgery
4
VSD ASD/VSDPacemaker
ASD/VSD
Family 10861 – TBX5 Y407X
00006
? ASD
closure
ASD + muscular
VSD
(surgically
closed)
A B
C D E
Family #12946 segregating the TFAP2b R285Q variant (A); Family #10861 segregating the TBX5 Y407X variant (B); Family #10006 segregating the TBX5 D166G
variant (C); Family #12637 segregating the elastin (ELN) (c.950-3C>G) variant (D); and Family #11756 segregating the NOTCH1 G200R variant (E). D [ mutation
positive;L[mutation negative; ¼ proband; ALCAPA ¼ anomalous origin of left coronary artery from pulmonary artery; ASD ¼ atrial septal defect; CHD ¼ congenital
heart disease; ECHO ¼ echocardiography; MAPCAS ¼ major aorto-pulmonary collateral arteries; PA ¼ pulmonary atresia; PDA ¼ patent ductus arteriosus; PTA ¼
persistent truncus arteriosus; SVAS ¼ supravalvular aortic stenosis; TOF ¼ tetralogy of Fallot; VSD ¼ ventricular septal defect.
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2503features: a patent ductus arteriosus; distinctive facial
appearance; and aplasia or hypoplasia of the middle
phalanges of the ﬁfth ﬁngers. No hand abnormalities
are present in Family #12946, but these may be subtle
and only detectable using radiological imaging. Some
individuals in the family had toe syndactyly, a less
common feature of Char syndrome (21). There is a
suggestion of incomplete penetrance in family 12946
with some mutation-positive individuals having no
history of patent ductus arteriosus or other cardiac
disease.
Variants in TBX5 were identiﬁed in 2 families pre-
sentingwith dominant forms of secundumatrial septal
defect and/or ventricular septal defect. Mutations in
TBX5 cause Holt-Oram syndrome, a highly penetrant,
autosomal dominant disorder characterized by upper
limb abnormalities and structural heart disease,
particularly cardiac septal defects (22). TBX5 plays acritical role in cardiac development and interacts with
other transcription factors, including GATA4 and
NKX2-5, to regulate cardiac chamber septation and
development of the conduction system (23,24).
Most of the mutations reported occurred within the
highly conserved T-box domain, which ranges from
amino acid residues 55 to 238. Interestingly, the
position of the mutation within the T-box seems to
affect phenotypic expression with mutations at
the N-terminal of the T-box resulting in a predomi-
nately cardiac phenotype, whereas mutations at the
C-terminal end result in a predominantly skeletal
phenotype (25). The ﬁrst variant identiﬁed in this
study, TBX5 D166G, which is in the T-box, was pres-
ent in all affected family members and absent in the
unaffected mother. Cross et al. (26) reported a variant
in close proximity to the one identiﬁed in our study,
G169R, in a family displaying primarily cardiac
CENTRAL ILLUSTRATION NGS Gene Panel Study to Identify Inherited Variants for Structural Heart Disease
16 families with strong histories of structural heart disease
were analyzed for presence of gene variants from a
gene panel of 57 genes previously implicated in congenital heart disease  
In 7 families (44%)
no causal gene variants
were present 
Further research is required 
to identify a possible gene 
variant at the root of the
family’s heart disease
i.e. Exome sequencing
Further research is required 
to identify a possible gene  
variant at the root of the
family’s heart disease
i.e. Exome sequencing and 
functional analysis
Identifying the causal gene variant within each family will allow for:
• Family planning and recurrence risk estimates 
• Further screening for associated conditions (including 
conduction defects, cardiomyopathies) in all mutation-
positive family members
• Explanations for heart disease within the family
• Genetic personalized counseling for family members
In 4 families (25%)
gene variants of unknown
significance were present 
In 5 families (31%)
pathogenic, causal gene variants were present
(In 3 of these patients the heart defect was possibly
associated with a previously undiagnosed syndrome)
Blue, G.M. et al. J Am Coll Cardiol. 2014; 64(23):2498–506.
A gene panel covering 57 genes previously implicated in congenital heart disease (CHD) identiﬁed 13 potential disease-causing variants in
9 families. Of these, pathogenic variants were seen in 5 families (31%). NGS ¼ next-generation sequencing.
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2504defects and only subtle skeletal abnormalities; thus it
is possible that mild skeletal abnormalities have been
overlooked in this family. Further studies on the
G169R variant revealed that while there was little or
no effect on DNA binding afﬁnity, this variant resul-
ted in a complete loss of synergistic transcription
activity between TBX5 and NKX2-5 (27). The second
TBX5 variant (TBX5 Y407X) was identiﬁed in a family
with septal defects and conduction defects, another
common feature of Holt-Oram syndrome. This
particular variant is a stop-gain resulting in a trun-
cated protein product at position 407. Termination
occurs in the last coding exon of the gene and would
therefore be predicted to escape nonsense-mediated
decay. However, reports of a stop-gain at position
456, known to cause Holt-Oram syndrome, support
the pathogenicity of this variant (28). Segregation of
this variant with the cardiac phenotype provides
additional support for its pathogenic status. Whereas
this family has undergone clinical genetic assess-
ment, subtle skeletal features such as distally placed
thumbs or mildly hypoplastic clavicles might have
been missed without radiological imaging.
A splicing variant, c.950-3C>G, in the elastin
(ELN) gene was identiﬁed in Family #12637 withsupravalvular aortic stenosis. Williams syndrome is
caused by deletion of a region at 7q11.23, which
includes ELN and several other genes. Supravalvular
aortic stenosis is present in 60% to 84% of affected
individuals and is attributed to haploinsufﬁciency for
ELN (29). Mutations in ELN have been reported in
nonsyndromic forms of supravalvular aortic stenosis,
too, and many of these are splice-site variants (30,31).
The splice-site variant identiﬁed in the proband of
Family #12637 affects a conserved residue in the 30
acceptor splice site in intron 17, resulting in premature
splicing according to multiple splicing prediction pro-
grams. Incorrect splicing produces an altered amino
acid sequence for exon 18 prior to termination at po-
sition 323. Segregation studies further support patho-
genicity as all 3 affected family members (and no
unaffected individuals) are heterozygous for this
variant.
NOTCH1 has predominantly been linked to
left-sided cardiac lesions (32); however, in Family
#11756, variant G200R was identiﬁed in 2 second
cousins displaying right-sided lesions. Second cousins
only share one-thirty-second (3.13%) of their DNA, so
the observation that these affected cousins share this
novel, “probably pathogenic” variant (as predicted
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2505by all 3 prediction programs used) suggests a role in
disease mechanism. Yet the apparently incomplete
penetrance in the family members linking the 2 sec-
ond cousins makes it difﬁcult to be certain of the role
of this variant as the cause of CHD in this family.
The reported NKX2-5 variant, R25C, identiﬁed in
Family #13041, has previously been linked to a num-
ber of CHD lesions, including tetralogy of Fallot,
interrupted aortic arch, and hypoplastic left heart
syndrome (15–17). The signiﬁcance of this variant,
however, remains unclear as it has been detected in
healthy control subjects (33) and is present in ESP
with a frequency of w1%. Functional analysis of this
variant demonstrated a slight impairment in dimer-
ization in the mutant protein versus wild-type
protein (34), suggesting a possible role in disease
development. Still, the fact that the unaffected
mother in Family #13041 is homozygous for the R25C
variant suggests this variant is likely benign.
To summarize, in 3 of the 5 families with patho-
genic variants, the heart defect could be associated
with a previously undiagnosed syndrome, albeit with
minimal extracardiac manifestations in most affected
individuals. However, irrespective of whether the
eventual diagnosis is syndromic or nonsyndromic
CHD, this information has the potential to make a
profound impact on these families. In some families,
promising causal variants were identiﬁed, such as the
TBX20 R420X variant in Family #12944; however,
segregation analyses were not supportive of patho-
genicity. Although a stop-gain variant is hard to
ignore, the fact that this variant is present in ESP
(albeit very rare) and is near the end of the protein
product as opposed to within the highly conserved
T-box, together with nonsegregation with disease in
the family, points toward it not being a sole contrib-
utor to disease phenotype.
STUDY LIMITATIONS. Our ﬁndings highlight the
importance of variant segregation analyses in deter-
mining variant pathogenicity, even if this approach
did not identify pathogenic variants in the majority of
families. This may have occurred because these
families may carry mutations in genes not targeted by
this study given that we chose to examine the most
highly implicated genes in CHD causation. Alterna-
tively, these families may carry mutations in these
genes, but they lie in regions other than those
captured and resequenced here. Also, although there
was good reason to think these were families with
Mendelian inheritance with CHD due to mutations
in a single gene per family, in some of the families,
>1 pathogenic variant may have been segregating,
resulting in CHD due to di– or oligogenic inheritance,as suggested in the study by Granados-Riveron et al.
(35). This could cause misleading results in segrega-
tion studies, so that a genuinely pathogenic variant is
wrongly rejected due to apparent nonsegregation
with phenotype. Lastly, it is possible that $1 of
the families, despite appearing to show Mendelian
inheritance, actually had CHD due to multifactorial
causation. Future exome sequencing may be able to
resolve some of these possibilities.
Addit ional var i ants . We have demonstrated the
success of the CHD panel in identifying pathogenic
variants in families with apparently Mendelian forms
of CHD. Our efforts raise further questions, however,
regarding the additional protein-altering variants
detected in the CHD cases and their relative con-
tribution to disease phenotype. We identiﬁed a
signiﬁcant increase in “probably damaging” variants,
“indels, nonsense, and splice” variants, and a number
of “rare” and “low” frequency variants (MAF <0.05)
in CHD cases versus control subjects. At present, we
do not fully understand the signiﬁcance and contri-
bution of these additional variants toward the cardiac
phenotype, but they may be genetic modiﬁers of
disease. A larger cohort would be required to clarify
their signiﬁcance and contribution toward disease.
CONCLUSIONS
Families with Mendelian forms of CHD can be
considered candidates for genetic screening using a
gene panel–based approach. The value of being able to
offer families a chance at obtaining a genetic diagnosis
cannot be underestimated both from a clinical and
psychosocial perspective. The ability to identify
pathogenic variants in families has signiﬁcant impli-
cations for future family planning as well as assess-
ments for associated conditions, such as conduction
defects or cardiomyopathies in certain genes. We have
demonstrated a promising diagnostic yield in familial
forms of CHD; however, further research and devel-
opment of this tool, particularly in a clinical setting,
are required to assess its practical applications.
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PERSPECTIVES
COMPETENCY IN PATIENT CARE: In up to 31% of
families in which multiple relatives are affected by CHD,
a genetic basis can be identiﬁed, and rapid screening for
disease-related genes can be facilitated using advanced
sequencing technologies.
TRANSLATIONAL OUTLOOK: Although the diag-
nostic yield of CHD gene panels appears promising in
identifying familial forms of CHD, further research is
needed to assess its utility in clinical practice.
Blue et al. J A C C V O L . 6 4 , N O . 2 3 , 2 0 1 4
NGS for Congenital Heart Disease D E C E M B E R 1 6 , 2 0 1 4 : 2 4 9 8 – 5 0 6
2506RE F E RENCE S1. Blue GM, Kirk EP, Sholler GF, Harvey RP,
Winlaw DS. Congenital heart disease: current
knowledge about causes and inheritance. Med J
Aust 2012;197:155–9.
2. Burn J, Goodship J. Congenital heart disease. In:
Rimoin D, Connor J, Pyeritz R, Korf B, editors.
Emery and Rimoin’s Principles and Practice of
Medical Genetics. 4th edition. London: Churchill
Livingstone, 2002:1239–72.
3. Wessels MW, Willems PJ. Genetic factors in
non-syndromic congenital heart malformations.
Clin Genet 2010;78:103–23.
4. Sikkema-Raddatz B, Johansson LF, de Boer EN,
et al. Targeted next-generation sequencing can
replace Sanger sequencing in clinical diagnostics.
Hum Mutat 2013;34:1035–42.
5. Rehm HL. Disease-targeted sequencing: a
cornerstone in the clinic. Nat Rev Genet 2013;14:
295–300.
6. Johansson H, Isaksson M, Sörqvist EF, et al.
Targeted resequencing of candidate genes using
selector probes. Nucleic Acids Res 2011;39:e8.
7. Lieber DS, Calvo SE, Shanahan K, et al. Targeted
exome sequencing of suspected mitochondrial
disorders. Neurology 2013;80:1762–70.
8. Meder B, Haas J, Keller A, et al. Targeted next-
generation sequencing for the molecular genetic
diagnostics of cardiomyopathies. Circ Cardiovasc
Genet 2011;4:110–22.
9. Wooderchak-Donahue W, O’Fallon B, Furtado L,
et al. A direct comparison of next generation
sequencing enrichment methods using an aortop-
athy gene panel–clinical diagnostics perspective.
BMC Med Genomics 2012;5:50.
10. Arrington CB, Bleyl SB, Matsunami N, et al.
Exome analysis of a family with pleiotropic con-
genital heart disease. Circ Cardiovasc Genet 2012;
5:175–82.
11. Greenway SC, McLeod R, Hume S, et al., for the
FORGE Canada Consortium. Exome sequencing
identiﬁes a novel variant in ACTC1 associated with
familial atrial septal defect. Can J Cardiol 2014;30:
181–7.
12. Zaidi S, Choi M, Wakimoto H, et al. De novo
mutations in histone-modifying genes in congen-
ital heart disease. Nature 2013;498:220–3.
13. Warburton D, Ronemus M, Kline J, et al. The
contribution of de novo and rare inherited copy
number changes to congenital heart disease in an
unselected sample of children with conotruncaldefects or hypoplastic left heart disease. Hum
Genet 2014;133:11–27.
14. Soemedi R, Wilson IJ, Bentham J, et al.
Contribution of global rare copy-number variants
to the risk of sporadic congenital heart disease.
Am J Hum Genet 2012;91:489–501.
15. Benson DW, Silberbach GM, Kavanaugh-
McHugh A, et al. Mutations in the cardiac tran-
scription factor NKX2.5 affect diverse cardiac
developmental pathways. J Clin Invest 1999;104:
1567–73.
16. McElhinney DB, Geiger E, Blinder J,
Benson DW, Goldmuntz E. NKX2.5 mutations in
patients with congenital heart disease. J Am Coll
Cardiol 2003;42:1650–5.
17. Rauch R, Hofbeck M, Zweier C, et al. Compre-
hensive genotype–phenotype analysis in 230
patients with tetralogy of Fallot. J Med Genet
2010;47:321–31.
18. Patel C, Silcock L, McMullan D, Brueton L,
Cox H. TBX5 intragenic duplication: a family with
an atypical Holt-Oram syndrome phenotype. Eur J
Hum Genet 2012;20:863–9.
19. Kirk EP, Sunde M, Costa MW, et al. Mutations
in cardiac T-box factor gene TBX20 are associated
with diverse cardiac pathologies, including defects
of septation and valvulogenesis and cardiomyop-
athy. Am J Hum Genet 2007;81:280–91.
20. Zhao F, Weismann CG, Satoda M, et al. Novel
TFAP2B mutations that cause Char syndrome
provide a genotype-phenotype correlation. Am J
Hum Genet 2001;69:695–703.
21. Slavotinek A, Clayton-Smith J, Super M.
Familial patent ductus arteriosus: a further case of
CHAR syndrome. Am J Med Genet 1997;71:229–32.
22. Basson CT, Bachinsky DR, Lin RC, et al. Muta-
tions in human TBX5 [corrected] cause limb and
cardiac malformation in Holt-Oram syndrome. Nat
Genet 1997;15:30–5.
23. Garg V, Kathiriya IS, Barnes R, et al. GATA4
mutations cause human congenital heart defects
and reveal an interaction with TBX5. Nature 2003;
424:443–7.
24. Hiroi Y, Kudoh S, Monzen K, et al. Tbx5
associates with Nkx2-5 and synergistically pro-
motes cardiomyocyte differentiation. Nat Genet
2001;28:276–80.
25. Ghosh TK, Packham EA, Bonser AJ,
Robinson TE, Cross SJ, Brook JD. Characterization
of the TBX5 binding site and analysis of mutationsthat cause Holt-Oram syndrome. Hum Mol Genet
2001;10:1983–94.
26. Cross SJ, Ching Y-H, Li QY, et al. The mutation
spectrum in Holt-Oram syndrome. J Med Genet
2000;37:785–7.
27. Fan C, Liu M, Wang Q. Functional analysis
of TBX5 missense mutations associated with
Holt-Oram syndrome. J Biol Chem 2003;278:
8780–5.
28. Posch M, Perrot A, Berger F, Özcelik C.
Molecular genetics of congenital atrial septal
defects. Clin Res Cardiol 2010;99:137–47.
29. Delio M, Pope K, Wang T, et al. Spectrum
of elastin sequence variants and cardiovas-
cular phenotypes in 49 patients with Williams-
Beuren syndrome. Am J Med Genet A 2013;161:
527–33.
30. Metcalfe K, Rucka AK, Smoot L, et al. Elastin:
mutational spectrum in supravalvular aortic
stenosis. Eur J Hum Genet 2000;8:955–63.
31. Micale L, Turturo MG, Fusco C, et al. Iden-
tiﬁcation and characterization of seven novel
mutations of elastin gene in a cohort of patients
affected by supravalvular aortic stenosis. Eur J
Hum Genet 2009;18:317–23.
32. Garg V, Muth AN, Ransom JF, et al. Mutations
in NOTCH1 cause aortic valve disease. Nature
2005;437:270–4.
33. Goldmuntz E, Geiger E, Benson DW. NKX2.5
mutations in patients with tetralogy of Fallot.
Circulation 2001;104:2565–8.
34. Kasahara H, Lee B, Schott JJ, et al. Loss of
function and inhibitory effects of human CSX/
NKX2.5 homeoprotein mutations associated with
congenital heart disease. J Clin Invest 2000;106:
299–308.
35. Granados-Riveron JT, Pope M, Bu’lock FA,
et al. Combined mutation screening of NKX2-5,
GATA4, and TBX5 in congenital heart disease:
multiple heterozygosity and novel mutations.
Congenit Heart Dis 2012;7:151–9.KEY WORDS congenital heart defects,
gene panel, molecular diagnosisAPPENDIX For a supplemental Methods
section as well as tables and ﬁgures, please see
the online version of this paper.
